Coversin matches Soliris in Phase II
Akari held an R&D day on 24 April 2017, at which it announced the interim results from the Phase II clinical trial of Coversin for paroxysmal nocturnal hemoglobinuria (PNH). The four patients who completed the study met the primary endpoint of hemolysis within 1.8x the upper limit of normal (ULN), with the average at 1.5x ULN, which is considered optimal control similar to Soliris. Additionally, it announced the initiation of an atypical hemolytic uremic syndrome (aHUS) Phase II in Q217 and two new programs: bullous pemphigoid (BP), and mucous membrane pemphigoid (MMP).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.